Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Stock Forecast

Stock Price Forecast

The 4 analysts that cover Lineage Cell Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $4.25, which forecasts a 147.09% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $9.00.

Price Target: $4.25 (+147.09%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$2.00	$4.25	$3.00	$9.00
Change	+16.28%	+147.09%	+74.42%	+423.26%

Analyst Ratings

The average analyst rating for Lineage Cell Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jun '25	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25
Strong Buy	5	5	4	4	4	4
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $2	Strong Buy	Maintains	$2	+16.28%	Nov 25, 2025
Joseph Pantginis HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $9	Strong Buy	Maintains	$9	+423.26%	Nov 24, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $2	Strong Buy	Maintains	$2	+16.28%	Aug 27, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $2	Strong Buy	Maintains	$2	+16.28%	Aug 14, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $2	Strong Buy	Maintains	$2	+16.28%	Aug 5, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

10.00M

Increased by 5.24%

from 9.50M

Revenue Next Year

22.67M

Increased by 126.78%

from 10.00M

EPS This Year

-0.27

from -0.09

EPS Next Year

-0.07

from -0.27

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.83M	4.34M	14.70M	8.95M	9.50M	10.00M	22.67M
Revenue Growth	-48.05%	137.73%	238.70%	-39.16%	6.19%	5.24%	126.78%
EPS	-0.14	-0.26	-0.15	-0.12	-0.09	-0.27	-0.07
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	9	9

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	12.2M	36.0M
Avg	10.0M	22.7M
Low	6.1M	3.3M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	28.6%	260.1%
Avg	5.2%	126.8%
Low	-36.0%	-67.2%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	-0.15	-0.04
Avg	-0.27	-0.07
Low	-0.33	-0.10

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.